| Similar Articles |
|---|
 |
The Motley Fool
August 1, 2008
Brian Lawler |
Is $60 a Share Enough for ImClone? Bristol-Myers Squibb announced a $60-per-share offer for ImClone Systems, but are shareholders going to go for the deal?   |
The Motley Fool
September 11, 2008
Brian Lawler |
ImClone and Bristol-Myers' Unfinished Business ImClone rejects Bristol's offer, but likely isn't done dealing with it yet. |
The Motley Fool
September 22, 2008
Brian Lawler |
Why Bristol-Myers Won't Pull Its ImClone Bid Bristol-Myers might drop its cash bid of $60 per share to acquire longtime partner ImClone Systems. |
The Motley Fool
October 4, 2006
Brian Lawler |
Unwelcome Guests at ImClone ImClone's board of directors votes against Carl Icahn's proposed removal of six company directors. Short-term shareholders that are able to cash out with Icahn, will possibly have a nice gain to take home. |
The Motley Fool
June 11, 2008
Brian Lawler |
He Said, Biogen Said Pharmaceutical Biogen Idec's battle with Carl Icahn is coming to a head. |
The Motley Fool
January 29, 2008
Brian Lawler |
Icahn Tries to Board USS Biogen Carl Icahn and the funds that he runs announce that they will try to get elected to three seats on the board of directors at Biogen Idec. |
The Motley Fool
November 8, 2007
Brian Lawler |
Let the Biogen Bidding Begin Speculation of bidding by big-pharma companies for Biogen IDEC cause the shares to rise. Investors, take note. |
The Motley Fool
September 24, 2008
Brian Lawler |
Bristol-Myers Puts Icahn and ImClone to the Test Despite trying to project different intentions last week, pharma giant Bristol-Myers Squibb raised its bid for ImClone Systems. |
The Motley Fool
March 23, 2010
Brian Orelli |
Icahn and Biogen Kiss and Make Up He gets one more seat on the board, so what's next? |
The Motley Fool
September 29, 2006
Brian Lawler |
ImClone Under Siege Board member Carl Icahn moves to take control, and it appears as though shareholders agree. |
The Motley Fool
January 29, 2010
Brian Orelli |
Icahn Back to Batter Biogen The old guy has tenacity. |
The Motley Fool
February 23, 2010
Brian Orelli |
Icahn Puts His Proxy Fight Where His Money Is How patient will Carl Icahn be with Genzyme's turnaround plan? That's the $270 million question -- the value of Icahn's shares, based on his holdings at the end of the year. |
The Motley Fool
September 21, 2006
Brian Lawler |
ImClone's Board Shakeup A new face in the boardroom heralds change for the troubled company. Shareholders yesterday elected notorious corporate raider Carl Icahn to the company's board of directors. |
The Motley Fool
December 13, 2007
Brian Lawler |
Biogen Can't Find a Buyer After formally putting itself up for sale two months ago, Biogen Idec announces that it can't find any takers. |
The Motley Fool
June 4, 2009
Brian Orelli |
Ignore Icahn's Hoopla Carl Icahn and his fights with management at Biogen's Idec make for entertaining news coverage, but investors shouldn't spend too much time analyzing how the antics are going to affect the share price. |
The Motley Fool
January 30, 2009
Brian Orelli |
Icahn's Next Target Activist investor Carl Icahn has decided to nominate a slate of five directors for the board of Amylin Pharmaceuticals, of which he owns 8.3%. |
The Motley Fool
September 15, 2008
Brian Orelli |
Side Effects Don't Scare Icahn Billionaire investor Carl Icahn upped his stake in the drug company by almost 50% and now owns 7.3% of the company. |
The Motley Fool
May 29, 2008
Brian Lawler |
Icahn Girds for Biogen Battle The activist investor officially launches his bid to usurp Biogen's board of directors. |
The Motley Fool
June 19, 2008
Brian Orelli |
Live From Bio: Activist Investors Activist investors throw a fit and try to get management changes when they're not happy, like Carl Icahn has done with ImClone Systems and tried to do with Biogen Idec. As they become more common, how are companies dealing with them? |
The Motley Fool
October 25, 2006
Brian Lawler |
Earnings Soothe ImClone Investors For long-term shareholders of ImClone stock, it will be hard to bask in the glory of ImClone's positive earnings for long. Numerous looming issues surround the company, including the Yeda patent dispute, coming competition from Amgen's Vectibix, and possible shareholder shenanigans from Icahn. |
The Motley Fool
November 18, 2008
Brian Orelli |
Icahn's Next Biotech Adventure With ImClone done, he's got his eye focused elsewhere. |
The Motley Fool
October 7, 2008
Brian Orelli |
Eli Lilly's Risky Gamble Eli Lilly is desperate, and the high acquisition price of ImClone shows it. |
The Motley Fool
October 2, 2008
Brian Orelli |
Will Lilly Buy ImClone's Troubles? Eli Lilly is reportedly ImClone's mystery suitor. Would it be a good deal? |
The Motley Fool
September 1, 2009
Rick Aristotle Munarriz |
Icahn Handles the Truth at Yahoo! Carl Icahn has sold shares of struggling online giant Yahoo! in each of the past three trading days, enough to take his stake below 5%. |
The Motley Fool
May 13, 2009
Brian Orelli |
Icahn's an Energizer Pit Bull He keeps going and doesn't let go. |
The Motley Fool
July 23, 2008
Rick Aristotle Munarriz |
Icahn's Spotty Track Record Carl Icahn and Yahoo! have made nice, in advance of next week's meeting, but will the peace last? Or is the current calm just the eye of the hurricane? |
The Motley Fool
January 29, 2007
Brian Lawler |
ImClone Fights The Competition The drug developer's performance has been alright, but the competition is heating up. Investors, take note. |
The Motley Fool
April 28, 2008
Brian Lawler |
ImClone on the Upswing The pharmaceutical's latest results show continuing improvement. |
The Motley Fool
July 8, 2008
Rick Aristotle Munarriz |
Doesn't Yahoo! Get a Say? Billionaire investor Carl Icahn and Microsoft insist that only a new boardroom -- ideally populated by the slate of directors that Icahn is proposing -- will lead Microsoft to reopen acquisition talks with Yahoo!. |
The Motley Fool
August 21, 2008
Brian Lawler |
PDL BioPharma's Partnership Makes Sense Bristol-Myers assumes some of the risk of developing a drug for bone marrow cancer. |
The Motley Fool
August 29, 2008
Brian Lawler |
Will Biopharma Acquisitions Never Cease? In both the size and quantity of proposed deals, the past 24 months have been busier than ever for biopharma dealmakers. What's behind all this activity? |
The Motley Fool
February 6, 2009
Brian Orelli |
Icahn vs. Biogen: Round 2 On the heels of an announcement that he'll try to get seats on Amylin Pharmaceuticals' board, Icahn is also angling for seats on Biogen Idec's board. |
The Motley Fool
March 10, 2010
Brian Orelli |
You Paid How Much for That? Abbott steps up where Biogen Idec wouldn't. |
The Motley Fool
December 31, 2007
Brian Lawler |
The Biotech Year in Review Following the biotech sector is never dull, and 2007 was no exception to the rule. Let's take a look at the highlights and lowlights of 2007. |
The Motley Fool
February 17, 2010
Anders Bylund |
Who Is Icahn Selling To Now? Lionsgate is looking to buy the Miramax studio from Walt Disney in what looks like a good stylistic match. Will Carl Icahn turn the tables on that deal and coax a bid out of Disney? |
The Motley Fool
August 1, 2007
Brian Lawler |
ImClone Inches Along ImClone reports slower than expected sales growth with its lead cancer fighting drug, Erbitux. ImClone needs to expand the use of Erbitux into new markets to return to a period of sustained top-line growth. |
The Motley Fool
April 27, 2007
Brian Lawler |
Tracking ImClone The biopharmaceutical releases first-quarter financial results. Investors, take note. |
The Motley Fool
August 20, 2010
Brian Orelli |
This Billionaire Likes Biotech. Should You? It depends on how much you trust management. |
The Motley Fool
April 20, 2004
Charly Travers |
Great Googly Moogly, ImClone The biopharmaceutical company's stock is going crazy again. |
The Motley Fool
June 1, 2009
Brian Orelli |
Going Up for All the Wrong Reasons Bristol-Myers has been identified as Elan's mystery bidder. So what? |
The Motley Fool
October 27, 2010
Selena Maranjian |
When Hostile Takeovers Get Ugly Conflict between companies and potential buyers can spill over to hurt shareholders. |
The Motley Fool
May 16, 2008
Mac Greer |
Fool Video: Icahn Bares His Teeth, Craig's Cyst, and 5 Stocks Approaching Greatness Can Craigslist delete eBay? Will Icahn deliver for Microsoft? These questions are discussed in this video. |
The Motley Fool
October 16, 2007
Brian Lawler |
Questions Surround a Biogen Deal Rumors swirl around Biogen after it publicly announces that it's for sale. Investors, take note. |
The Motley Fool
May 19, 2008
Brian Orelli |
What Will Icahn Do With Amylin? Carl Icahn recently took an initial position now worth around $200 million in Amylin Pharmaceuticals, and stockholders must be wondering about his motivation for the purchase. |
BusinessWeek
October 29, 2007
Hamm & Grover |
Tech Gets the Icahn Treatment Carl Icahn is shaking up the landscape in Silicon Valley as companies' revenue growth slows. |
The Motley Fool
October 1, 2008
Brian Orelli |
Is Pfizer the Mystery Bidder? A few signals that Pfizer might be the one bidding on ImClone. |
InternetNews
July 20, 2009 |
Icahn Pushing Again for Yahoo-Microsoft Deal Carl Icahn, the billionaire investor who made so much trouble for Yahoo last year, has spoken out in favor of a deal with Microsoft, which reportedly could be announced as early as this week. |
BusinessWeek
March 5, 2007
Ronald Grover |
Just Don't Call Him A Raider Carl Icahn, who now styles himself a shareholder activist, prepares for battle with Motorola. |
The Motley Fool
June 10, 2010
Brian Orelli |
Cancel the Clowns: Icahn Avoids a Circus The billionaire investor backs down from a fight. He withdrew his slate of candidates to join Genzyme's board yesterday. |
The Motley Fool
May 22, 2008
Brian Lawler |
Enzon Shareholders Steal the Show A shareholder tussle overshadows clinical trial data. |
